Literature DB >> 31505490

Urine Osmolality and Renal Outcome in Patients with Chronic Kidney Disease: Results from the KNOW-CKD.

Mi Jung Lee1, Tae Ik Chang2, Joongyub Lee3, Yeong Hoon Kim4, Kook-Hwan Oh5, Sung Woo Lee6, Soo Wan Kim7, Jung Tak Park8, Tae-Hyun Yoo8, Shin-Wook Kang8, Kyu Hun Choi8, Curie Ahn5, Seung Hyeok Han9.   

Abstract

BACKGROUND: Urine osmolality indicates the ability of the kidney to concentrate the urine and reflects the antidiuretic action of vasopressin. However, results about the association between urine osmolality and adverse renal outcomes in chronic kidney disease (CKD) are conflicting. We investigated the association between urine osmolality and adverse renal outcomes in a nationwide prospective CKD cohort.
METHODS: A total of 1,999 CKD patients were categorized into 3 groups according to their urine osmolality tertiles. Primary outcome was a composite of 50% decline in the estimated glomerular filtration rate (eGFR), initiation of dialysis, or kidney transplantation.
RESULTS: During a mean follow-up of 35.2 ± 19.0 months, primary outcome occurred in 432 (21.6%) patients; 240 (36.4%), 162 (24.3%), and 30 (4.5%) in the lowest, middle, and highest tertiles, respectively. Low urine osmolality was independently associated with a greater risk of CKD progression (hazard ratio [HR], 1.71; 95% confidence interval [CI], 1.12-2.59). This association was particularly evident in patients with CKD stages 3-4 (per 10 mosm/kg decrease; HR, 1.02; 95% CI, 1.00-1.03). Adding urine osmolality to a base model with conventional factors significantly increased the ability to predict CKD progression (C-statistics, 0.86; integrated discrimination improvement [IDI], 0.021; both p < 0.001). However, adding both urine osmolality and eGFR did not further improve the predictive ability compared with the addition of eGFR only (C-statistics, p = 0.29; IDI, p = 0.09).
CONCLUSIONS: Low urine osmolality was an independent risk factor for adverse renal outcomes in CKD patients, but its predictive ability did not surpass eGFR. Thus, kidney function should be considered while interpreting the clinical significance of urine osmolality.
© 2019 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Chronic kidney disease; Estimated glomerular filtration rate; Outcome; Urine osmolality

Mesh:

Year:  2019        PMID: 31505490     DOI: 10.1159/000502291

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  5 in total

1.  Considerations in Controlling for Urine Concentration for Biomarkers of Kidney Disease Progression After Acute Kidney Injury.

Authors:  Yumeng Wen; Heather Thiessen-Philbrook; Dennis G Moledina; James S Kaufman; W Brian Reeves; Nasrollah Ghahramani; T Alp Ikizler; Alan S Go; Kathleen D Liu; Eddie D Siew; Jonathan Himmelfarb; Paul L Kimmel; Chi-Yuan Hsu; Chirag R Parikh
Journal:  Kidney Int Rep       Date:  2022-04-06

Review 2.  The KNOW-CKD Study: What we have learned about chronic kidney diseases.

Authors:  Kook-Hwan Oh; Minjung Kang; Eunjeong Kang; Hyunjin Ryu; Seung Hyeok Han; Tae-Hyun Yoo; Soo Wan Kim; Dong-Wan Chae; Kyu-Beck Lee; Sue K Park; Yeong Hoon Kim; Curie Ahn
Journal:  Kidney Res Clin Pract       Date:  2020-06-30

3.  The Relationships between Water Intake and Hydration Biomarkers and the Applications for Assessing Adequate Total Water Intake among Young Adults in Hebei, China.

Authors:  Jianfen Zhang; Guansheng Ma; Songming Du; Na Zhang
Journal:  Nutrients       Date:  2021-10-26       Impact factor: 5.717

4.  The Effect of Metformin in Diabetic and Non-Diabetic Rats with Experimentally-Induced Chronic Kidney Disease.

Authors:  Mohammed Al Za'abi; Badreldin H Ali; Yousuf Al Suleimani; Sirin A Adham; Haytham Ali; Priyadarsini Manoj; Mohammed Ashique; Abderrahim Nemmar
Journal:  Biomolecules       Date:  2021-05-30

5.  The association of urine osmolality with decreased kidney function and/or albuminuria in the United States.

Authors:  Boonsong K Kitiwan; Sarinnapha M Vasunilashorn; Heather J Baer; Kenneth Mukamal; Stephen P Juraschek
Journal:  BMC Nephrol       Date:  2021-09-10       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.